Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 Monotherapy in Advanced Solid Tumors
NCT05360368Phase 1Unknown
- Sponsor
- Henlius
- Start
- Mar 2023
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimurutamab in solid tumor, sponsored by Henlius. Primary endpoints: Incidence of Treatment-Related Adverse Events at 2 years, Proportion of patients experiencing dose limiting toxicity events and 1 more. Status: unknown.
02
Drugs
pimurutamab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05360368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360368.